1. |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
|
2. |
Guo L, Wang C, Qiu X, et al. Colorectal cancer immune infiltrates: significance in patient prognosis and immunotherapeutic efficacy. Front Immunol, 2020, 11: 1052.
|
3. |
Fan XJ, Wan XB, Fu XH, et al. Phosphorylated p38, a negative prognostic biomarker, complements TNM staging prognostication in colorectal cancer. Tumour Biol, 2014, 35(10): 10487-10495.
|
4. |
Fridman WH, Zitvogel L, Sautès-Fridman C, et al. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol, 2017, 14(12): 717-734.
|
5. |
Bhattacharya S, Andorf S, Gomes L, et al. ImmPort: disseminating data to the public for the future of immunology. Immunol Res, 2014, 58(2-3): 234-239.
|
6. |
Kamarudin AN, Cox T, Kolamunnage-Dona R. Time-dependent ROC curve analysis in medical research: current methods and applications. BMC Med Res Methodol, 2017, 17(1): 53.
|
7. |
Wolbers M, Koller MT, Witteman JC, et al. Prognostic models with competing risks: methods and applicationto coronary risk prediction. Epidemiology, 2009, 20(4): 555-561.
|
8. |
Li T, Fan J, Wang B, et al. TIMER: A web server for compre-hensive analysis of tumor-infiltrating immune cells. Cancer Res, 2017, 77(21): e108-e110.
|
9. |
Lin A, Zhang J, Luo P. Crosstalk between the MSI status and tumor microenvironment in colorectal cancer. Front Immunol, 2020, 11: 2039.
|
10. |
Wang Z, Song Q, Yang Z, et al. Construction of immune-related risk signature for renal papillary cell carcinoma. Cancer Med, 2019, 8(1): 289-304.
|
11. |
Song Q, Shang J, Yang Z, et al. Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma. J Transl Med, 2019, 17(1): 70.
|
12. |
Hu D, Zhou M, Zhu X. Deciphering immune-associated genes to predict survival in clear cell renal cell cancer. Biomed Res Int, 2019, 2019: 2506843.
|
13. |
Qiu H, Hu X, He C, et al. Identification and validation of an individualized prognostic signature of bladder cancer based on seven immune related genes. Front Genet, 2020, 11: 12.
|
14. |
Jin H, Rugira T, Ko YS, et al. ESM-1 overexpression is involved in increased tumorigenesis of radiotherapy-resistant breast cancer cells. Cancers (Basel), 2020, 12(6): 1363.
|
15. |
Kano K, Sakamaki K, Oue N, et al. Impact of the ESM-1 gene expression on outcomes in stage Ⅱ/Ⅲ gastric cancer patients who received adjuvant S-1 chemotherapy. In Vivo, 2020, 34(1): 461-467.
|
16. |
Kim JH, Park MY, Kim CN, et al. Expression of endothelial cell-specific molecule-1 regulated by hypoxia inducible factor-1α in human colon carcinoma: impact of ESM-1 on prognosis and its correlation with clinicopathological features. Oncol Rep, 2012, 28(5): 1701-1708.
|
17. |
Kang YH, Ji NY, Han SR, et al. ESM-1 regulates cell growth and metastatic process through activation of NF-κB in colorectal cancer. Cell Signal, 2012, 24(10): 1940-1949.
|
18. |
Yildirim K, Colak E, Aktimur R, et al. Clinical value of CXCL5 for determining of colorectal cancer. Asian Pac J Cancer Prev, 2018, 19(9): 2481-2484.
|
19. |
Zhang W, Wang H, Sun M, et al. CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target. Cancer Commun (Lond), 2020, 40(2-3): 69-80.
|
20. |
Hu B, Fan H, Lv X, et al. Prognostic significance of CXCL5 expression in cancer patients: a meta-analysis. Cancer Cell Int, 2018, 18: 68.
|
21. |
Zhang Y, Zheng S, Liao N, et al. CircCTNNA1 acts as a ceRNA for miR-363-3p to facilitate the progression of colorectal cancer by promoting CXCL5 expression. J Biol Res (Thessalon), 2021, 28(1): 7.
|
22. |
Chen C, Xu ZQ, Zong YP, et al. CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the AKT/NF-κB pathway in colorectal cancer. Cell Death Dis, 2019, 10(3): 178.
|
23. |
Zhao J, Ou B, Han D, et al. Tumor-derived CXCL5 promotes human colorectal cancer metastasis through activation of the ERK/Elk-1/Snail and AKT/GSK3β/β-catenin pathways. Mol Cancer, 2017, 16(1): 70.
|
24. |
Novillo A, Gaibar M, Romero-Lorca A, et al. Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports. World J Gastroenterol, 2020, 26(16): 1979-1986.
|
25. |
Ieta K, Tanaka F, Yokobori T, et al. Clinicopathological significance of stanniocalcin 2 gene expression in colorectal cancer. Int J Cancer, 2009, 125(4): 926-931.
|
26. |
Yang XL, Liu KY, Lin FJ, et al. CCL28 promotes breast cancer growth and metastasis through MAPK-mediated cellular anti-apoptosis and pro-metastasis. Oncol Rep, 2017, 38(3): 1393-1401.
|
27. |
Dimberg J, Hugander A, Wågsäter D. Protein expression of the chemokine, CCL28, in human colorectal cancer. Int J Oncol, 2006, 28(2): 315-319.
|
28. |
Miao Y, Wang J, Ma X, et al. Identification prognosis-associated immune genes in colon adenocarcinoma. Biosci Rep, 2020, 40(11): BSR20201734.
|
29. |
Raufman JP, Dawson PA, Rao A, et al. Slc10a2-null mice uncover colon cancer-promoting actions of endogenous fecal bile acids. Carcinogenesis, 2015, 36(10): 1193-1200.
|
30. |
Li Y, Wang P, Ye D, et al. IGHG1 induces EMT in gastric cancer cells by regulating TGF-β/SMAD3 signaling pathway. J Cancer, 2021, 12(12): 3458-3467.
|
31. |
Michele S, Mariachiara B, Emanuela P, et al. UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response. Oncotarget, 2016, 7(28): 44113-44128.
|
32. |
Kikuchi T, Mimura K, Ashizawa M, et al. Characterization of tumor-infiltrating immune cells in relation to microbiota in colorectal cancers. Cancer Immunol Immunother, 2020, 69(1): 23-32.
|
33. |
Fan CW, Kopsida M, Liu YB, et al. Prognostic heterogeneity of MRE11 based on the location of primary colorectal cancer is caused by activation of different immune signals. Front Oncol, 2020, 9: 1465.
|
34. |
Hsu YL, Chen YJ, Chang WA, et al. Interaction between tumor-associated dendritic cells and colon cancer cells contributes to tumor progression via CXCL1. Int J Mol Sci, 2018, 19(8): 2427.
|
35. |
De la Fuente López M, Landskron G, Parada D, et al. The relationship between chemokines CCL2, CCL3, and CCL4 with the tumor microenvironment and tumor-associated macrophage markers in colorectal cancer. Tumour Biol, 2018, 40(11): 1010428318810059.
|